Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119


Polymicrobial airway bacterial communities in adult bronchiectasis patients.

Purcell P, Jary H, Perry A, Perry JD, Stewart CJ, Nelson A, Lanyon C, Smith DL, Cummings SP, De Soyza A.

BMC Microbiol. 2014 May 20;14:130. doi: 10.1186/1471-2180-14-130.


A novel microbiota stratification system predicts future exacerbations in bronchiectasis.

Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, Rivett DW, McGuckin MA, Serisier DJ.

Ann Am Thorac Soc. 2014 May;11(4):496-503. doi: 10.1513/AnnalsATS.201310-335OC.


Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.

Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, Ennis M, Boucher RC, Wolfgang MC, Elborn JS.

Am J Respir Crit Care Med. 2013 May 15;187(10):1118-26. doi: 10.1164/rccm.201210-1937OC.


Differences of lung microbiome in patients with clinically stable and exacerbated bronchiectasis.

Byun MK, Chang J, Kim HJ, Jeong SH.

PLoS One. 2017 Aug 22;12(8):e0183553. doi: 10.1371/journal.pone.0183553. eCollection 2017.


The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.

Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ.

Lancet Respir Med. 2014 Dec;2(12):988-96. doi: 10.1016/S2213-2600(14)70213-9. Epub 2014 Oct 14. Erratum in: Lancet Respir Med. 2015 Apr;3(4):e15.


Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance.

McDonnell MJ, Jary HR, Perry A, MacFarlane JG, Hester KL, Small T, Molyneux C, Perry JD, Walton KE, De Soyza A.

Respir Med. 2015 Jun;109(6):716-26. doi: 10.1016/j.rmed.2014.07.021. Epub 2014 Aug 29.


Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition.

Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, Serisier DJ.

Thorax. 2013 Aug;68(8):731-7. doi: 10.1136/thoraxjnl-2012-203105. Epub 2013 Apr 6.


Lobar distribution in non-cystic fibrosis bronchiectasis predicts bacteriologic pathogen treatment.

Izhakian S, Wasser WG, Fuks L, Vainshelboim B, Fox BD, Fruchter O, Kramer MR.

Eur J Clin Microbiol Infect Dis. 2016 May;35(5):791-6. doi: 10.1007/s10096-016-2599-7. Epub 2016 Feb 12.


Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients.

Cox MJ, Turek EM, Hennessy C, Mirza GK, James PL, Coleman M, Jones A, Wilson R, Bilton D, Cookson WO, Moffatt MF, Loebinger MR.

PLoS One. 2017 Feb 7;12(2):e0170622. doi: 10.1371/journal.pone.0170622. eCollection 2017.


Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis.

Taylor SL, Rogers GB, Chen AC, Burr LD, McGuckin MA, Serisier DJ.

Ann Am Thorac Soc. 2015 May;12(5):701-7. doi: 10.1513/AnnalsATS.201411-513OC.


Complexity, temporal stability, and clinical correlates of airway bacterial community composition in primary ciliary dyskinesia.

Rogers GB, Carroll MP, Zain NM, Bruce KD, Lock K, Walker W, Jones G, Daniels TW, Lucas JS.

J Clin Microbiol. 2013 Dec;51(12):4029-35. doi: 10.1128/JCM.02164-13. Epub 2013 Sep 25.


Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities.

van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, Daniels TW, Carroll MP, Parkhill J, Bruce KD.

ISME J. 2011 May;5(5):780-91. doi: 10.1038/ismej.2010.175. Epub 2010 Dec 9.


Cohort Study of Airway Mycobiome in Adult Cystic Fibrosis Patients: Differences in Community Structure between Fungi and Bacteria Reveal Predominance of Transient Fungal Elements.

Kramer R, Sauer-Heilborn A, Welte T, Guzman CA, Abraham WR, Höfle MG.

J Clin Microbiol. 2015 Sep;53(9):2900-7. doi: 10.1128/JCM.01094-15. Epub 2015 Jul 1.


The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.

Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, Wolfgang MC.

PLoS One. 2012;7(9):e45001. doi: 10.1371/journal.pone.0045001. Epub 2012 Sep 26.


Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.

Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R.

Eur Respir J. 1997 Aug;10(8):1754-60.


Secreted mucins and airway bacterial colonization in non-CF bronchiectasis.

Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, Fardon TC, Finch S, Mateus EF, Garcia-Bellmunt L, Castillo D, Vidal S, Sanchez-Reus F, Restrepo MI, Chalmers JD.

Respirology. 2015 Oct;20(7):1082-8. doi: 10.1111/resp.12595. Epub 2015 Jul 14.


Determining the influence of environmental and patient specific factors on the polymicrobial communities of the cystic fibrosis airway.

Nelson A, Perry A, Perry JD, Bourke SJ, Cummings SP, De Soyza A.

Antonie Van Leeuwenhoek. 2013 Apr;103(4):755-62. doi: 10.1007/s10482-012-9857-1. Epub 2012 Nov 24.


Predominant pathogen competition and core microbiota divergence in chronic airway infection.

Rogers GB, van der Gast CJ, Serisier DJ.

ISME J. 2015 Jan;9(1):217-25. doi: 10.1038/ismej.2014.124. Epub 2014 Jul 18.


Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.

Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT.

Am J Respir Crit Care Med. 2012 Oct 1;186(7):657-65. doi: 10.1164/rccm.201203-0487OC. Epub 2012 Jun 28.


Supplemental Content

Support Center